Pain
Conditions
Brief summary
The primary purpose of this study is to demonstrate the bioequivalence of two ibuprofen arginine granules 400 milligram (mg) formulations under fasting and fed conditions in Chinese healthy adult participants. The secondary purpose of this study is to assess the pharmacokinetic and safety profile of the test and reference preparations.
Detailed description
The bioequivalence study adopts a single-center, randomized, open-label, single-dose, two-treatment, two-sequence, two-period, two-cohort, two-way crossover design with at least 2-day washout period, under both fasting and fed conditions in Chinese healthy adult participants. It will be planned to enroll approximately 84 participants out of which the first 34 participants for the fasted cohort and the subsequent 50 participants for the fed cohort receiving ibuprofen arginine granules 400 mg. Participants will be randomly assigned to either one of the 2 treatment (Test or Reference product) sequences in a 1:1 ratio within fasted cohort and fed cohort.
Interventions
DRUGIbuprofen arginine granules 400 mg
Experimental- Ibuprofen arginine granules 400 mg, one sachet administration containing 400 mg ibuprofen granules.
DRUGIbuprofen arginine granules 400 mg (Spedifen)
Marketed drug- Ibuprofen arginine granules 400 mg (Spedifen), one sachet administration containing 400 mg ibuprofen granules.
Sponsors
HALEON
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* Participants provision of a signed and dated informed consent and/or assent document indicating that the participant has been informed of all pertinent aspects of the study before any assessment is performed. * Participants who is willing and able to comply with scheduled visits, treatment plan, laboratory tests, study restrictions, lifestyle considerations and other study procedures. * Healthy Participants, which is defined as in general good physical health, as judged by the investigator and no clinically significant relevant abnormalities identified by a detailed medical history, full physical examination, including vital signs, 12-lead electrocardiogram (ECG) and laboratory tests. * A Participants with a Body Mass Index (BMI) of 19-26 kilogram per meter square (kg/m\^2) (including 19, excluding 26) \[BMI equal to (=) weight (Kilogram \[kg\])/height\^2 (m\^2)\]; and a total body weight more than or equal to \>= 50 kilogram (kg) for males, and \>= 45 kg for females, at screening. * Participants with one negative polymerase chain reaction (PCR) or antigen test (on Day-1) for active Coronavirus disease 2019 (COVID-19). * Participants of childbearing potential and are sexually active and at risk for pregnancy must agree to use a highly effective method of contraception throughout the study and for at least 30 days after the last dose of assigned treatment. Female participant who are not of childbearing potential must meet requirements in the Contraception section of protocol.
Exclusion criteria
* Known or suspected intolerance or hypersensitivity or photosensitivity to the investigational products (or closely related compounds) or any of their stated ingredients. * Allergy to skin disinfecting agents, tape, or latex rubber, whenever appropriate substitutions cannot be applied or in the investigator's opinion may pose a risk to the candidate. * Diagnosis of long QT syndrome or QTcF \> 450 millisecond (msec) at screening. * Clinically significant vital sign abnormalities (systolic blood pressure lower than 90 or over 140 millimeters of mercury (mmHg), diastolic blood pressure lower than 60 or over 90 mmHg, or pulse rate less than 50 or over 100 beats per minute \[bpm\]). * Use of any medication (including over-the-counter medications and Chinese herbal and traditional remedies) within 2 weeks before first scheduled study drug administration or within less than 10 times the elimination half-life of the concomitant medication (whichever is longer) or is anticipated to require any concomitant medication during that period or at any time throughout the study. Allowed treatments are: 1. systemic contraceptives and hormone replacement therapy, as long as female participant is on stable treatment for at least 3 months before first scheduled study drug administration and continues treatment throughout the study. 2. occasional use of acetaminophen (up to 2 grams \[g\] in 24 hours). * Participants has a history of drug abuse or has positive urine drug abuse screening at screening or on Day-1. * Participants reported regular consumption of \> 5 cups (1 cup approximately 250 milliliters \[mL\]) of coffee or tea per day (or equivalent consumption of \>= 500 mg caffeine per day using other products). Or consuming any beverages or food containing caffeine, such as coffee, tea, coke, chocolate, etc., within 48 hours prior to screening. * Smoking or history of regular use of tobacco- or nicotine-containing products (for example nicotine patch, electronic cigarette) within 6 months prior to screening. Or a participant who is unwilling to abstain from tobacco or nicotine containing product use during the study. * Evidence, as reported by an alcohol breath testing, for current alcohol abuse or reports a regular average alcohol consumption exceeding 18 g (women) or 35 g (men) of pure alcohol per day, that is (i.e.) 1 drink/day for women or 2 drinks/day for men \[1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor\] within 6 months prior to screening. * Participation in other clinical trials involving investigational drug(s) within 90 days prior to screening. * Those who have blood donation (including component donation) or blood loss \>= 400 mL within 3 months before the study or have blood transfusion; those who have blood donation (including component donation) or blood loss \>= 200 mL within 1 month before the study (except female physiological blood loss). * Acute or chronic medical condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study. Or any condition not identified in the protocol that in the opinion of the investigator would confound the evaluation and interpretation of the study data or may put the participant at risk. * Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease within the last 5 years that may increase the risk associated with study participation. * Clinically relevant chronic or acute infectious illnesses or febrile infections within two weeks prior to start of the study. * Participation with known COVID-19 positive contacts in the past 14 days. * Participation with signs or symptoms highly suggestive of COVID-19 (including not limited to fever, cough, chills, new loss of taste or smell, etc.) that also align with the clinical judgement of the investigator, within 14 days of inpatient admission as defined by World Health Organization (WHO) or local guidance. * Any vaccination, including COVID-19 vaccine, within 14 days prior to the first dose of investigational products. * Any surgical or medical condition which may significantly alter the absorption, distribution, metabolism or excretion of any drug substance but not limited to any of the following: 1. History of major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, bowel resection, gastric bypass, gastric stapling or gastric banding (note: this is not applicable for minor abdominal surgery without significant tissue resection, e.g., appendectomy and herniorrhaphy). 2. History of inflammatory bowel disease. 3. History or current evidence of renal disease or impaired renal function at screening as indicated by abnormal levels of estimated glomerular filtration rate (eGFR) less than (\<) 90 mL/min/1.73m\^2 or the presence of clinically significant abnormal urinary constituents (e.g., albuminuria). 4. History or current evidence of ongoing hepatic disease or impaired hepatic function at screening. A candidate will be excluded if more than one of the following lab value deviations are found: 1. Aspartate aminotransferase (AST) (\>= 1.2 upper limit of normal \[ULN\]), alanine transaminase (ALT) (\>= 1.2 ULN), 2. Gamma-glutamyl transferase (GGT) (\>= 1.2 ULN), alkaline phosphatase (ALP) (\>= 1.2 ULN), 3. Bilirubin (\>= 1.5 ULN) or creatine kinase (CK) (\>= 3 ULN). A single deviation from the above values is acceptable and will not exclude the candidate, unless specifically advised by the investigator. 5. Evidence of urinary obstruction or difficulty in voiding at screening. 6. History or clinical evidence at screening of pancreatic injury or pancreatitis. * Pregnant or lactating women, or participant intending to become pregnant over the duration of the study. * Positive results (or out of normal range) any of the virology tests for hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), hepatitis C virus (HCV) antibody, or human immunodeficiency virus (HIV) antibody or syphilis. * Participants reports consumption of any drug metabolizing enzyme (for example (e.g.), CYP3A4 or other cytochrome P450 enzymes) inducing or inhibiting aliments, beverages or food supplements (e.g., broccoli, Brussels sprouts, grapefruit, grapefruit juice, star fruit, St. John's Wort etc.) within 2 weeks prior to screening until admission to the unit. * Performance of strenuous physical exercise (body building, high performance sports) from 2 weeks prior to admission. * Those who are not suitable for participation in this study as determined by the investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Area Under the Plasma Concentration Time Curve From Time Zero to Last Observed Concentration at Time t (AUC[0-t]) for Ibuprofen in Fasted Conditions | Pre-dose (within 2 hours prior to dosing) and at 5, 10, 15, 20, 30, 45, 60, 75, 90, 105, 120 minutes, 2.5, 3, 4, 6, 8, and 12 hours post-dose | AUC(0-t) was defined as area under the plasma concentration-time curve from time zero to last observed concentration at time t calculated using the linear up log down trapezoidal rule. Blood samples were collected at indicated timepoints for the analysis of AUC(0-t). Pharmacokinetic (PK) parameters were determined by non-compartmental analysis. |
| Area Under the Plasma Concentration Time Curve From Time Zero to Time Infinity (AUC [0-inf]) for Ibuprofen in Fasted Conditions | Pre-dose (within 2 hours prior to dosing) and at 5, 10, 15, 20, 30, 45, 60, 75, 90, 105, 120 minutes, 2.5, 3, 4, 6, 8, and 12 hours post-dose | AUC (0-inf) was defined as area under the plasma concentration versus time curve calculated from time 0 to infinity, computed as AUC(0-inf) = AUC(0-t) +Ct/λz where Ct was the plasma concentration at the last measurable sampling time point and λz was the terminal elimination rate constant. Blood samples were collected at indicated timepoints for the analysis of AUC(0-inf). PK parameters were determined by non-compartmental analysis. |
| Observed Maximum Plasma Concentration (Cmax) for Ibuprofen in Fasted Conditions | Pre-dose (within 2 hours prior to dosing) and at 5, 10, 15, 20, 30, 45, 60, 75, 90, 105, 120 minutes, 2.5, 3, 4, 6, 8, and 12 hours post-dose | Cmax was defined as maximum observed post-dose plasma concentration for ibuprofen. Blood samples were collected at indicated timepoints for the analysis of Cmax. PK parameters were determined by non-compartmental analysis. |
| Cmax for Ibuprofen in Fed Conditions | Pre-dose (within 2 hours prior to dosing) and 10, 30, 45, 60, 75, 90, 120 minutes, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10 and 12 hours post-dose | Cmax was defined as maximum observed post-dose plasma concentration for ibuprofen. Blood samples were collected at indicated timepoints for the analysis of Cmax. PK parameters were determined by non-compartmental analysis. |
| AUC(0-t) for Ibuprofen in Fed Conditions | Pre-dose (within 2 hours prior to dosing) and 10, 30, 45, 60, 75, 90, 120 minutes, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10 and 12 hours post-dose | AUC(0-t) was defined as area under the plasma concentration-time curve from time zero to last observed concentration at time t calculated using the linear up log down trapezoidal rule. Blood samples were collected at indicated timepoints for the analysis of AUC(0-t). PK parameters were determined by non-compartmental analysis. |
| AUC (0-inf) for Ibuprofen in Fed Conditions | Pre-dose (within 2 hours prior to dosing) and 10, 30, 45, 60, 75, 90, 120 minutes, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10 and 12 hours post-dose | AUC (0-inf) was defined as area under the plasma concentration versus time curve calculated from time 0 to infinity, computed as AUC(0-inf) = AUC(0-t) +Ct/λz where Ct was the plasma concentration at the last measurable sampling time point and λz was the terminal elimination rate constant. Blood samples were collected at indicated timepoints for the analysis of AUC(0-inf). PK parameters were determined by non-compartmental analysis. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| λz of Ibuprofen in Fed Conditions | Pre-dose (within 2 hours prior to dosing) and 10, 30, 45, 60, 75, 90, 120 minutes, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10 and 12 hours post-dose | λz was defined as terminal elimination rate constant estimated by log-linear regression of the terminal part of the plasma concentration versus time curve. Blood samples were collected at indicated timepoints for the analysis of λz. PK parameters were determined by non-compartmental analysis. |
| Time to Reach Maximum Plasma Concentration (Tmax) of Ibuprofen in Fasted Conditions | Pre-dose (within 2 hours prior to dosing) and at 5, 10, 15, 20, 30, 45, 60, 75, 90, 105, 120 minutes, 2.5, 3, 4, 6, 8, and 12 hours post-dose | Blood samples were collected at indicated timepoints for the analysis of Tmax. PK parameters were determined by non-compartmental analysis. |
| %AUCex of Ibuprofen in Fed Conditions | Pre-dose (within 2 hours prior to dosing) and 10, 30, 45, 60, 75, 90, 120 minutes, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10 and 12 hours post-dose | %AUCex was calculated as %AUCex = (1- AUC\[0-t\] /AUC\[0-inf\])\*100%. Blood samples were collected at indicated timepoints for the analysis of %AUCex. PK parameters were determined by non-compartmental analysis. |
| Elimination Half-life (t1/2) of Ibuprofen in Fasted Conditions | Pre-dose (within 2 hours prior to dosing) and at 5, 10, 15, 20, 30, 45, 60, 75, 90, 105, 120 minutes, 2.5, 3, 4, 6, 8, and 12 hours post-dose | t1/2 was defined as elimination half-life calculated as t1/2 = ln (2)/λz where λz was terminal elimination rate constant. Blood samples were collected at indicated timepoints for the analysis of t1/2. PK parameters were determined by non-compartmental analysis. |
| Terminal Elimination Rate Constant (λz) of Ibuprofen in Fasted Conditions | Pre-dose (within 2 hours prior to dosing) and at 5, 10, 15, 20, 30, 45, 60, 75, 90, 105, 120 minutes, 2.5, 3, 4, 6, 8, and 12 hours post-dose | λz was defined as terminal elimination rate constant estimated by log-linear regression of the terminal part of the plasma concentration versus time curve. Blood samples were collected at indicated timepoints for the analysis of λz. PK parameters were determined by non-compartmental analysis. |
| Percentage of Extrapolated Area of AUC(0-inf) (%AUCex) of Ibuprofen in Fasted Conditions | Pre-dose (within 2 hours prior to dosing) and at 5, 10, 15, 20, 30, 45, 60, 75, 90, 105, 120 minutes, 2.5, 3, 4, 6, 8, and 12 hours post-dose | %AUCex was calculated as %AUCex = (1- AUC\[0-t\] /AUC\[0-inf\])\*100%. Blood samples were collected at indicated timepoints for the analysis of %AUCex. PK parameters were determined by non-compartmental analysis. |
| Tmax of Ibuprofen in Fed Conditions | Pre-dose (within 2 hours prior to dosing) and 10, 30, 45, 60, 75, 90, 120 minutes, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10 and 12 hours post-dose | Blood samples were collected at indicated timepoints for the analysis of Tmax. PK parameters were determined by non-compartmental analysis. |
| t1/2 of Ibuprofen in Fed Conditions | Pre-dose (within 2 hours prior to dosing) and 10, 30, 45, 60, 75, 90, 120 minutes, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10 and 12 hours post-dose | t1/2 was defined as elimination half-life calculated as t1/2 = ln (2)/λz where λz was terminal elimination rate constant. Blood samples were collected at indicated timepoints for the analysis of t1/2. PK parameters were determined by non-compartmental analysis. |
Countries
China
Participant flow
Recruitment details
This study was conducted at a single center in China.
Pre-assignment details
A total of 235 participants were screened of which 34 participants were enrolled in fasted cohort and 50 participants were enrolled in fed cohort. Participants were randomized in 1:1 ratio within each cohort (fasted and fed) to receive either one of the 2 treatment sequence: Test (T) product followed by Reference (R) product (TR) or Reference product followed by Test product (RT) as per cross-over design.
Participants by arm
| Arm | Count |
|---|---|
| Fasted Cohort: Test Product-Reference Product (TR) Participants received one sachet of ibuprofen arginine granules 400 mg (test product), orally, once on Day 1 of Period 1 under fasting conditions followed by one sachet of ibuprofen arginine granules 400 mg (Spedifen) (reference product), orally, once on Day 1 of Period 2 under fasting conditions. Participants were instructed to take the study product after an overnight fast of at least 10 hours by dissolving it in 240 mL of warm water. There was a wash-out period of at least two days between the administration of each product. | 17 |
| Fasted Cohort: Reference Product-Test Product (RT) Participants received one sachet of ibuprofen arginine granules 400 mg (Spedifen) (reference product), orally, once on Day 1 of Period 1 under fasting conditions followed by one sachet of ibuprofen arginine granules 400 mg (test product), orally, once on Day 1 of Period 2 under fasting conditions. Participants were instructed to take the study product after an overnight fast of at least 10 hours by dissolving it in 240 mL of warm water. There was a wash-out period of at least two days between administration of each product. | 17 |
| Fed Cohort: Test Product-Reference Product (TR) Participants received one sachet of ibuprofen arginine granules 400 mg (test product), orally, once on Day 1 of Period 1 under fed conditions followed by one sachet of ibuprofen arginine granules 400 mg (Spedifen) (reference product), orally, once on Day 1 of Period 2 under fed conditions. Participants were instructed to take the study product after a high-fat/high-calorie meal by dissolving it in 240 mL of warm water. There was a wash-out period of at least two days between the administration of each product. | 25 |
| Fed Cohort: Reference Product-Test Product (RT) Participants received one sachet of ibuprofen arginine granules 400 mg (Spedifen) (reference product), orally, once on Day 1 of Period 1 under fed conditions followed by one sachet of ibuprofen arginine granules 400 mg (test product), orally, once on Day 1 of Period 2 under fed conditions. Participants were instructed to take the study product after a high-fat/high-calorie meal by dissolving it in 240 mL of warm water. There was a wash-out period of at least two days between administration of each product. | 25 |
| Total | 84 |
Baseline characteristics
| Characteristic | Fasted Cohort: Test Product-Reference Product (TR) | Fasted Cohort: Reference Product-Test Product (RT) | Fed Cohort: Test Product-Reference Product (TR) | Fed Cohort: Reference Product-Test Product (RT) | Total |
|---|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 17 Participants | 17 Participants | 25 Participants | 25 Participants | 84 Participants |
| Race/Ethnicity, Customized Han | 17 Participants | 16 Participants | 24 Participants | 25 Participants | 82 Participants |
| Race/Ethnicity, Customized Other | 0 Participants | 1 Participants | 1 Participants | 0 Participants | 2 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 17 Participants | 17 Participants | 25 Participants | 25 Participants | 84 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Sex: Female, Male Female | 4 Participants | 5 Participants | 12 Participants | 6 Participants | 27 Participants |
| Sex: Female, Male Male | 13 Participants | 12 Participants | 13 Participants | 19 Participants | 57 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 34 | 0 / 34 | 0 / 50 | 0 / 50 |
| other Total, other adverse events | 6 / 34 | 5 / 34 | 11 / 50 | 10 / 50 |
| serious Total, serious adverse events | 0 / 34 | 0 / 34 | 0 / 50 | 0 / 50 |
Outcome results
Primary
Area Under the Plasma Concentration Time Curve From Time Zero to Last Observed Concentration at Time t (AUC[0-t]) for Ibuprofen in Fasted Conditions
AUC(0-t) was defined as area under the plasma concentration-time curve from time zero to last observed concentration at time t calculated using the linear up log down trapezoidal rule. Blood samples were collected at indicated timepoints for the analysis of AUC(0-t). Pharmacokinetic (PK) parameters were determined by non-compartmental analysis.
Time frame: Pre-dose (within 2 hours prior to dosing) and at 5, 10, 15, 20, 30, 45, 60, 75, 90, 105, 120 minutes, 2.5, 3, 4, 6, 8, and 12 hours post-dose
Population: Pharmacokinetic Parameter Set was defined as the evaluable PK parameter data set obtained from randomized participants who received at least one dose of investigational product.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Fasted Cohort: Ibuprofen Arginine Granules 400 mg (Test) | Area Under the Plasma Concentration Time Curve From Time Zero to Last Observed Concentration at Time t (AUC[0-t]) for Ibuprofen in Fasted Conditions | 122.2406 hour*micrograms per milliliter | Geometric Coefficient of Variation 20.2 |
| Fasted Cohort: Ibuprofen Arginine Granules 400 mg (Spedifen) (Reference) | Area Under the Plasma Concentration Time Curve From Time Zero to Last Observed Concentration at Time t (AUC[0-t]) for Ibuprofen in Fasted Conditions | 122.1489 hour*micrograms per milliliter | Geometric Coefficient of Variation 21.3 |
90% CI: [0.9698, 1.0327]
Primary
Area Under the Plasma Concentration Time Curve From Time Zero to Time Infinity (AUC [0-inf]) for Ibuprofen in Fasted Conditions
AUC (0-inf) was defined as area under the plasma concentration versus time curve calculated from time 0 to infinity, computed as AUC(0-inf) = AUC(0-t) +Ct/λz where Ct was the plasma concentration at the last measurable sampling time point and λz was the terminal elimination rate constant. Blood samples were collected at indicated timepoints for the analysis of AUC(0-inf). PK parameters were determined by non-compartmental analysis.
Time frame: Pre-dose (within 2 hours prior to dosing) and at 5, 10, 15, 20, 30, 45, 60, 75, 90, 105, 120 minutes, 2.5, 3, 4, 6, 8, and 12 hours post-dose
Population: Pharmacokinetic Parameter Set.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Fasted Cohort: Ibuprofen Arginine Granules 400 mg (Test) | Area Under the Plasma Concentration Time Curve From Time Zero to Time Infinity (AUC [0-inf]) for Ibuprofen in Fasted Conditions | 124.8000 hour*micrograms per milliliter | Geometric Coefficient of Variation 21 |
| Fasted Cohort: Ibuprofen Arginine Granules 400 mg (Spedifen) (Reference) | Area Under the Plasma Concentration Time Curve From Time Zero to Time Infinity (AUC [0-inf]) for Ibuprofen in Fasted Conditions | 124.5173 hour*micrograms per milliliter | Geometric Coefficient of Variation 22 |
90% CI: [0.971, 1.0346]
Primary
AUC (0-inf) for Ibuprofen in Fed Conditions
AUC (0-inf) was defined as area under the plasma concentration versus time curve calculated from time 0 to infinity, computed as AUC(0-inf) = AUC(0-t) +Ct/λz where Ct was the plasma concentration at the last measurable sampling time point and λz was the terminal elimination rate constant. Blood samples were collected at indicated timepoints for the analysis of AUC(0-inf). PK parameters were determined by non-compartmental analysis.
Time frame: Pre-dose (within 2 hours prior to dosing) and 10, 30, 45, 60, 75, 90, 120 minutes, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10 and 12 hours post-dose
Population: Pharmacokinetic Parameter Set. Here, overall number analyzed is defined as the number of participants with data available for analysis of this outcome measure.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Fasted Cohort: Ibuprofen Arginine Granules 400 mg (Test) | AUC (0-inf) for Ibuprofen in Fed Conditions | 125.0559 hour*micrograms per milliliter | Geometric Coefficient of Variation 18.9 |
| Fasted Cohort: Ibuprofen Arginine Granules 400 mg (Spedifen) (Reference) | AUC (0-inf) for Ibuprofen in Fed Conditions | 128.9471 hour*micrograms per milliliter | Geometric Coefficient of Variation 22.8 |
90% CI: [0.9432, 1.0133]
Primary
AUC(0-t) for Ibuprofen in Fed Conditions
AUC(0-t) was defined as area under the plasma concentration-time curve from time zero to last observed concentration at time t calculated using the linear up log down trapezoidal rule. Blood samples were collected at indicated timepoints for the analysis of AUC(0-t). PK parameters were determined by non-compartmental analysis.
Time frame: Pre-dose (within 2 hours prior to dosing) and 10, 30, 45, 60, 75, 90, 120 minutes, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10 and 12 hours post-dose
Population: Pharmacokinetic Parameter Set.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Fasted Cohort: Ibuprofen Arginine Granules 400 mg (Test) | AUC(0-t) for Ibuprofen in Fed Conditions | 114.2490 hour*micrograms per milliliter | Geometric Coefficient of Variation 18.1 |
| Fasted Cohort: Ibuprofen Arginine Granules 400 mg (Spedifen) (Reference) | AUC(0-t) for Ibuprofen in Fed Conditions | 115.2125 hour*micrograms per milliliter | Geometric Coefficient of Variation 18 |
90% CI: [0.9755, 1.0081]
Primary
Cmax for Ibuprofen in Fed Conditions
Cmax was defined as maximum observed post-dose plasma concentration for ibuprofen. Blood samples were collected at indicated timepoints for the analysis of Cmax. PK parameters were determined by non-compartmental analysis.
Time frame: Pre-dose (within 2 hours prior to dosing) and 10, 30, 45, 60, 75, 90, 120 minutes, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10 and 12 hours post-dose
Population: Pharmacokinetic Parameter Set.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Fasted Cohort: Ibuprofen Arginine Granules 400 mg (Test) | Cmax for Ibuprofen in Fed Conditions | 17.8260 micrograms per milliliter | Geometric Coefficient of Variation 26.8 |
| Fasted Cohort: Ibuprofen Arginine Granules 400 mg (Spedifen) (Reference) | Cmax for Ibuprofen in Fed Conditions | 17.8573 micrograms per milliliter | Geometric Coefficient of Variation 25.9 |
90% CI: [0.9431, 1.0567]
Primary
Observed Maximum Plasma Concentration (Cmax) for Ibuprofen in Fasted Conditions
Cmax was defined as maximum observed post-dose plasma concentration for ibuprofen. Blood samples were collected at indicated timepoints for the analysis of Cmax. PK parameters were determined by non-compartmental analysis.
Time frame: Pre-dose (within 2 hours prior to dosing) and at 5, 10, 15, 20, 30, 45, 60, 75, 90, 105, 120 minutes, 2.5, 3, 4, 6, 8, and 12 hours post-dose
Population: Pharmacokinetic Parameter Set.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Fasted Cohort: Ibuprofen Arginine Granules 400 mg (Test) | Observed Maximum Plasma Concentration (Cmax) for Ibuprofen in Fasted Conditions | 54.400 micrograms per milliliter | Geometric Coefficient of Variation 16.7 |
| Fasted Cohort: Ibuprofen Arginine Granules 400 mg (Spedifen) (Reference) | Observed Maximum Plasma Concentration (Cmax) for Ibuprofen in Fasted Conditions | 55.368 micrograms per milliliter | Geometric Coefficient of Variation 15.9 |
90% CI: [0.9383, 1.0288]
Secondary
%AUCex of Ibuprofen in Fed Conditions
%AUCex was calculated as %AUCex = (1- AUC\[0-t\] /AUC\[0-inf\])\*100%. Blood samples were collected at indicated timepoints for the analysis of %AUCex. PK parameters were determined by non-compartmental analysis.
Time frame: Pre-dose (within 2 hours prior to dosing) and 10, 30, 45, 60, 75, 90, 120 minutes, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10 and 12 hours post-dose
Population: Pharmacokinetic Parameter Set. Here, overall number analyzed is defined as the number of participants with data available for analysis of this outcome measure.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Fasted Cohort: Ibuprofen Arginine Granules 400 mg (Test) | %AUCex of Ibuprofen in Fed Conditions | 7.9436 percentage of AUC | Geometric Coefficient of Variation 69.8 |
| Fasted Cohort: Ibuprofen Arginine Granules 400 mg (Spedifen) (Reference) | %AUCex of Ibuprofen in Fed Conditions | 8.3506 percentage of AUC | Geometric Coefficient of Variation 75.4 |
Secondary
Elimination Half-life (t1/2) of Ibuprofen in Fasted Conditions
t1/2 was defined as elimination half-life calculated as t1/2 = ln (2)/λz where λz was terminal elimination rate constant. Blood samples were collected at indicated timepoints for the analysis of t1/2. PK parameters were determined by non-compartmental analysis.
Time frame: Pre-dose (within 2 hours prior to dosing) and at 5, 10, 15, 20, 30, 45, 60, 75, 90, 105, 120 minutes, 2.5, 3, 4, 6, 8, and 12 hours post-dose
Population: Pharmacokinetic parameter set.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Fasted Cohort: Ibuprofen Arginine Granules 400 mg (Test) | Elimination Half-life (t1/2) of Ibuprofen in Fasted Conditions | 2.2023 hour |
| Fasted Cohort: Ibuprofen Arginine Granules 400 mg (Spedifen) (Reference) | Elimination Half-life (t1/2) of Ibuprofen in Fasted Conditions | 2.1300 hour |
Secondary
Percentage of Extrapolated Area of AUC(0-inf) (%AUCex) of Ibuprofen in Fasted Conditions
%AUCex was calculated as %AUCex = (1- AUC\[0-t\] /AUC\[0-inf\])\*100%. Blood samples were collected at indicated timepoints for the analysis of %AUCex. PK parameters were determined by non-compartmental analysis.
Time frame: Pre-dose (within 2 hours prior to dosing) and at 5, 10, 15, 20, 30, 45, 60, 75, 90, 105, 120 minutes, 2.5, 3, 4, 6, 8, and 12 hours post-dose
Population: Pharmacokinetic Parameter Set.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Fasted Cohort: Ibuprofen Arginine Granules 400 mg (Test) | Percentage of Extrapolated Area of AUC(0-inf) (%AUCex) of Ibuprofen in Fasted Conditions | 1.8299 percentage of AUC | Geometric Coefficient of Variation 46.6 |
| Fasted Cohort: Ibuprofen Arginine Granules 400 mg (Spedifen) (Reference) | Percentage of Extrapolated Area of AUC(0-inf) (%AUCex) of Ibuprofen in Fasted Conditions | 1.7393 percentage of AUC | Geometric Coefficient of Variation 43.8 |
Secondary
t1/2 of Ibuprofen in Fed Conditions
t1/2 was defined as elimination half-life calculated as t1/2 = ln (2)/λz where λz was terminal elimination rate constant. Blood samples were collected at indicated timepoints for the analysis of t1/2. PK parameters were determined by non-compartmental analysis.
Time frame: Pre-dose (within 2 hours prior to dosing) and 10, 30, 45, 60, 75, 90, 120 minutes, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10 and 12 hours post-dose
Population: Pharmacokinetic parameter set. Here, overall number analyzed is defined as the number of participants with data available for analysis of this outcome measure.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Fasted Cohort: Ibuprofen Arginine Granules 400 mg (Test) | t1/2 of Ibuprofen in Fed Conditions | 2.4053 hour |
| Fasted Cohort: Ibuprofen Arginine Granules 400 mg (Spedifen) (Reference) | t1/2 of Ibuprofen in Fed Conditions | 2.3995 hour |
Secondary
Terminal Elimination Rate Constant (λz) of Ibuprofen in Fasted Conditions
λz was defined as terminal elimination rate constant estimated by log-linear regression of the terminal part of the plasma concentration versus time curve. Blood samples were collected at indicated timepoints for the analysis of λz. PK parameters were determined by non-compartmental analysis.
Time frame: Pre-dose (within 2 hours prior to dosing) and at 5, 10, 15, 20, 30, 45, 60, 75, 90, 105, 120 minutes, 2.5, 3, 4, 6, 8, and 12 hours post-dose
Population: Pharmacokinetic Parameter Set.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Fasted Cohort: Ibuprofen Arginine Granules 400 mg (Test) | Terminal Elimination Rate Constant (λz) of Ibuprofen in Fasted Conditions | 0.3155 per hour | Geometric Coefficient of Variation 12.8 |
| Fasted Cohort: Ibuprofen Arginine Granules 400 mg (Spedifen) (Reference) | Terminal Elimination Rate Constant (λz) of Ibuprofen in Fasted Conditions | 0.3212 per hour | Geometric Coefficient of Variation 11.9 |
Secondary
Time to Reach Maximum Plasma Concentration (Tmax) of Ibuprofen in Fasted Conditions
Blood samples were collected at indicated timepoints for the analysis of Tmax. PK parameters were determined by non-compartmental analysis.
Time frame: Pre-dose (within 2 hours prior to dosing) and at 5, 10, 15, 20, 30, 45, 60, 75, 90, 105, 120 minutes, 2.5, 3, 4, 6, 8, and 12 hours post-dose
Population: Pharmacokinetic Parameter Set.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Fasted Cohort: Ibuprofen Arginine Granules 400 mg (Test) | Time to Reach Maximum Plasma Concentration (Tmax) of Ibuprofen in Fasted Conditions | 0.330 hour |
| Fasted Cohort: Ibuprofen Arginine Granules 400 mg (Spedifen) (Reference) | Time to Reach Maximum Plasma Concentration (Tmax) of Ibuprofen in Fasted Conditions | 0.330 hour |
Secondary
Tmax of Ibuprofen in Fed Conditions
Blood samples were collected at indicated timepoints for the analysis of Tmax. PK parameters were determined by non-compartmental analysis.
Time frame: Pre-dose (within 2 hours prior to dosing) and 10, 30, 45, 60, 75, 90, 120 minutes, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10 and 12 hours post-dose
Population: Pharmacokinetic Parameter Set.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Fasted Cohort: Ibuprofen Arginine Granules 400 mg (Test) | Tmax of Ibuprofen in Fed Conditions | 4.500 hour |
| Fasted Cohort: Ibuprofen Arginine Granules 400 mg (Spedifen) (Reference) | Tmax of Ibuprofen in Fed Conditions | 4.500 hour |
Secondary
λz of Ibuprofen in Fed Conditions
λz was defined as terminal elimination rate constant estimated by log-linear regression of the terminal part of the plasma concentration versus time curve. Blood samples were collected at indicated timepoints for the analysis of λz. PK parameters were determined by non-compartmental analysis.
Time frame: Pre-dose (within 2 hours prior to dosing) and 10, 30, 45, 60, 75, 90, 120 minutes, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10 and 12 hours post-dose
Population: Pharmacokinetic Parameter Set. Here, overall number analyzed is defined as the number of participants with data available for analysis of this outcome measure.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Fasted Cohort: Ibuprofen Arginine Granules 400 mg (Test) | λz of Ibuprofen in Fed Conditions | 0.2653 per hour | Geometric Coefficient of Variation 27 |
| Fasted Cohort: Ibuprofen Arginine Granules 400 mg (Spedifen) (Reference) | λz of Ibuprofen in Fed Conditions | 0.2515 per hour | Geometric Coefficient of Variation 39.3 |